October 2025 in “Journal of Cosmetic Dermatology” In this study, researchers found that type A botulinum toxin injections can reduce hypertrophic scars effectively, though more high-quality studies are needed to confirm the precision and stability of these therapeutic effects.
September 2025 in “Toxins” Botulinum toxins show promise in treating various conditions, but more research is needed for hair and scalp disorders.
September 2025 in “Clinics and Practice” This study found that six-month supplementation with fish-derived collagen peptides, calcium, and vitamin D3 improved skin hydration and elasticity and reduced hair loss in menopausal women, with collagen playing a dominant role in enhancing skin elasticity.
September 2025 in “Chinese Journal of Plastic and Reconstructive Surgery” This review reports that while botulinum toxin shows potential mechanisms for treating androgenetic alopecia, recent high-quality trials found no significant hair density improvement compared to placebo, indicating it can't yet replace traditional treatments.
August 2025 in “International Journal of Biological Macromolecules” A new hydrogel can kill resistant bacteria and help heal infected burn wounds.
August 2025 in “Annals of Indian Psychiatry” In a cross-sectional study, 46% of patients with androgenetic alopecia were found to have depression of borderline to moderate severity, while 62% reported no impact on their quality of life, emphasizing the need for awareness of psychiatric comorbidities among dermatologists.
This review reported that "Social Botox," encompassing both BTX cosmetic use and societal beauty pressures, significantly influences adolescent self-image, driven by social media and cultural standards, with mixed psychological outcomes, potentially enhancing confidence or exacerbating body dissatisfaction across various cultures.
July 2025 in “Actas Dermo-Sifiliográficas” This study found that a single session of botulinum toxin, whether administered subcutaneously or combined intramuscularly and subcutaneously, did not significantly improve hair density or hair quality in men with androgenetic alopecia after six months.
July 2025 in “Russian Journal of Clinical Dermatology and Venereology” This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.
June 2025 in “Reports of Vinnytsia National Medical University” In this study, young Ukrainian men with alopecia areata were found to generally have higher body circumference measurements, particularly in the upper limbs, lower limbs, and trunk, compared to healthy controls, suggesting potential markers for the disease and aiding personalized diagnosis and treatment approaches.
June 2025 in “Fayoum University Medical Journal/Fayoum University Medical Journal ” This study found that both intralesional minoxidil 8% and botulinum toxin type A were equally effective in treating female pattern hair loss, with no significant difference in results between the two treatments.
June 2025 in “Reports of Morphology” This study in young Ukrainian men found that specific body measurements, like shoulder width and tibia epiphysis width, are highly predictive of alopecia areata occurrence, though not for its progression, using discriminant models (p<0.001).
June 2025 in “Journal of Cosmetic Dermatology” In this study, a shampoo and hair tonic containing the botanical extract blend Asacurin100 reduced hair loss and improved scalp health in 35 male participants with androgenetic alopecia, without serious side effects, suggesting potential efficacy that warrants larger trials for confirmation.
May 2025 in “Actas Dermo-Sifiliográficas” The study did not find evidence to support using botulinum toxin as a treatment for androgenetic alopecia.
May 2025 in “International Journal of Biological Macromolecules” In this study, an innovative microneedle platform loaded with IGF-1 and modified collagen was reported to significantly promote hair regeneration, enhance neovascularization, and reduce inflammation in a mouse model of androgenetic alopecia, outperforming the commonly used minoxidil treatment.
This review discusses the use of botulinum toxin for hair and scalp disorders and reports mixed findings, with most studies showing mild or non-significant effects on hair growth.
March 2025 in “Journal of Cosmetic Dermatology” The study found that botulinum toxin-A significantly increased the diameter of the supratrochlear artery in a small patient group, suggesting potential vasodilatory benefits for treating ischemic conditions.
February 2025 in “Journal of Nutrients” This research reviews the scientific literature on bone broth extract, exploring its nutritional composition, potential health benefits, food industry applications, and risks such as heavy metal and antibiotic contamination. Results are not reported in this summary.
February 2025 in “Journal of Investigative Dermatology” DMG-Na may help reduce hair loss and improve hair growth, but more research is needed.
February 2025 in “Journal of Cosmetic Dermatology” This case report describes a 34-year-old Asian female who experienced prolonged localized facial blanching following botulinum toxin type A injection, marking the first such documented case in this population.
January 2025 in “Dermatologic Surgery” This meta-analysis and systematic review found that botulinum toxin injections significantly increased hair count in patients with androgenetic alopecia compared to controls, indicating promising efficacy and good safety.
January 2025 in “Frontiers in Genetics” In this study, researchers reported significant hair growth in an 8-year-old with hypotrichosis simplex of the scalp after treatment with a combination of oral botanical extracts and minoxidil, marking the first documented use of botanical extracts as a potential therapeutic approach for this condition.
January 2025 in “Regenerative Biomaterials” In this study, a new pH-responsive hydrogel composed of polyvinyl alcohol and boric acid was found to release salvianolic acid B effectively, reducing excessive scar formation and enhancing tissue regeneration during early-stage wound healing.
January 2025 in “Nanoscale” This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.
January 2025 in “Journal of Men s Health” This article reports that the rise in erectile dysfunction among young men may be linked to mental health issues and societal pressures, with online communities often encouraging risky substance use like anabolic steroids and finasteride, which can exacerbate psychological and physical health problems.
January 2025 in “Medical Archives” Body dysmorphia is common in women with PCOS, affecting their quality of life.
January 2025 in “International Journal of Trichology” This case report documents a rare instance of body-focused repetitive behavior in a 37-year-old male physician who compulsively pulled hair from his thighs due to exam stress, highlighting the variability in presentation and demographics of such disorders and the potential for psychiatric comorbidity.
December 2024 in “Qlantic Journal of Social Sciences and Humanities” This study found that among adult balding men in Rawalpindi and Islamabad, those seeking hair transplants exhibited higher levels of perfectionism and body dysmorphic disorder symptoms compared to those not seeking treatment.
December 2024 in “Reports of Vinnytsia National Medical University” In this study, young Ukrainian men with alopecia areata were found to have a "subpathological" body type, characterized by shorter lower limbs and longer upper limbs and torso compared to healthy peers.
December 2024 in “Jurnal Mandala Pharmacon Indonesia” In this study, high-dose oral administration of Ramania leaf ethanol extract in Wistar rats resulted in no significant acute toxicity symptoms, though gastric ulcers and hair loss were observed. The extract is classified as non-toxic under specified guidelines, with an LD50 greater than 5000 mg/kg.